StockNews.AI
MDBH
StockNews.AI
190 days

Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker Symbol

1. Invizyne Technologies rebrands to eXoZymes with new ticker 'EXOZ'. 2. Trading under the new symbol expected to start on February 12, 2025. 3. No actions required from existing shareholders for name change. 4. Invizyne focuses on enzyme-based biomanufacturing for various significant chemicals. 5. Management believes their technology may redefine traditional production methods.

5m saved
Insight
Article

FAQ

Why Neutral?

The rebranding indicates potential growth; however, it doesn't guarantee immediate market changes. Historical name changes often result in temporary price fluctuations without lasting impact.

How important is it?

The article provides significant information on a corporate rebranding, important for market perception but not central to MDBH's operations.

Why Short Term?

Initial trading under the new symbol may cause short-lived volatility, similar to prior name changes in biotech firms. Long-term growth depends more on operational performance than branding.

Related Companies

IZTCEXOZ
Trading Under New Ticker of “EXOZ” Expected to Begin February 12, 2025 February 10, 2025 11:00 ET  | Source: Invizyne Technologies, Inc. Monrovia, CA, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Today, Invizyne Technologies, Inc., (NASDAQ: IZTC) ("Invizyne"), a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, announced a corporate name change to eXoZymes, Inc. (“eXoZymes”) and an application for a new ticker symbol. The company expects trading under the new ticker symbol of “EXOZ” to begin on February 12, 2025, subject to final approvals. In connection with the corporate name change, Company branding, including the corporate website, will be updated accordingly. No action is required by existing shareholders with respect to the name and ticker symbol change. The Committee on Uniform Securities Identification Procedures (CUSIP) also confirmed the CUSIP number assigned to the Company's common stock will remain unchanged. About Invizyne Invizyne Technologies, Inc. is a cell-free enzyme-based biomanufacturing technology company headquartered in Monrovia, California. Invizyne is redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals, such as Active Pharmaceutical Ingredients (APIs), biofuels, food flavors, fragrances, cosmetics, etc. Management of Invizyne believes that its biomanufacturing platform, will be a significant alternative to the current methods of chemical compound production, which are generally chemical synthesis, natural extraction, and synthetic biology. For more information, please visit www.invizyne.com  Forward-Looking Statements This press release contains "forward-looking statements." These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as “aim”, "expect," "anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "might," "could," "intend," "shall" and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Invizyne's control. Invizyne's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors. The forward-looking statements included in this press release represent Invizyne's views as of the date of this press release. Invizyne anticipates that subsequent events and developments will cause its views to change. Invizyne undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Invizyne's views as of any date subsequent to the date of this press release. Media contacts:Lasse Görlitz, VP of Communications(858) 319-7135press@invizyne.com  Investor Relations Contact: IR@invizyne.com 

Related News